Muthiah Vaduganathan

Jan 23, 2025 | onlinelibrary.wiley.com | Safia Chatur |Muthiah Vaduganathan |Robert Fletcher |Vlado Perkovic

Introduction Patients with type 2 diabetes face heightened risk for the development of comorbid cardiovascular and kidney disease including heart failure (HF).1 The sodium–glucose cotransporter 2 (SGLT2) inhibitor canagliflozin has been shown to reduce the risk of HF hospitalization or cardiovascular death among patients with type 2 diabetes at high cardiovascular and kidney risk across a broad range of patient subgroups in the CANVAS and CREDENCE trials, respectively.2, 3 Loop diuretics are...

Nov 19, 2024 | hcplive.com | Muthiah Vaduganathan |Patrick Campbell

GLP-1 receptor agonists and combination incretin therapies have taken the medical community by storm in recent years with trial after trial proving benefits on outcomes across a multitude of diseases, including weight management, secondary prevention of cardiovascular disease, and, now, obesity-related heart failure with preserved ejection fraction (HFpEF) based on data from the SUMMIT trial.

Nov 7, 2024 | radcliffecvrm.com | Andrew Coats |Brad H Rovin |Jürgen Floege |Muthiah Vaduganathan

Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease. In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).

Oct 31, 2024 | jamanetwork.com | Jacob Pierce |Muthiah Vaduganathan |Gregg C. Fonarow |Uchechukwu Ikeaba

Key PointsQuestion  What is the prevalence and variability of sodium-glucose cotransporter-2 inhibitor (SGLT2i) use among patients with heart failure with reduced ejection fraction (HFrEF) in the US? Findings  In this cohort study including 49 399 patients hospitalized for HFrEF in the Get With The Guidelines–Heart Failure registry, 1 in 5 patients were discharged with prescriptions for SGLT2i therapy; rates were similarly low in patients with comorbid type 2 diabetes and chronic kidney disease.

Oct 9, 2024 | jacc.org | Muthiah Vaduganathan |Brian Claggett |Ian J. Kulac |Akshay S. Desai

AbstractBackgroundFinerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart failure (HF) with and without diabetes and/or CKD are not known. ObjectivesExamine the effects of finerenone on kidney outcomes in FINEARTS-HF, a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced or preserved ejection fraction.